Metotrexato

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metotrexato

Property Description
Active Ingredient Methotrexate (MTX)
Form Tablets, Solution for Injection
Pharmacological Class Antimetabolite, Antifolate
General Purpose Controls cell growth and modulates the immune system
Origin Synthetic (Folic Acid Analogue)

Metotrexato, known internationally as Methotrexate (MTX), is a specialized, synthetic pharmaceutical agent and a prescription-only medication. It is primarily classified as an antimetabolite and an antifolate drug, signifying its chemical ability to interfere with metabolic processes essential for cell multiplication. Its chemical structure is a deliberate analogue of folic acid (a B vitamin), allowing it to disrupt specific biological pathways.


What Type of Medicine is Metotrexato (Methotrexate)?

Metotrexato is an antifolate drug that acts by blocking an enzyme necessary for the synthesis of key components of cellular DNA and RNA. This drug is clinically recognized for its essential role in two distinct areas: high-dose use as an antineoplastic agent (used against abnormal cell growth) and low-dose use as a Disease-Modifying Antirheumatic Drug (DMARD). This molecule's specific antagonism of the folate pathway drives both its cytotoxic and immunosuppressive properties. As a single-ingredient product, the active substance is Methotrexate, often formulated as Methotrexate sodium.


Composition, Forms, and General Purpose

The active ingredient, Methotrexate, is available in multiple pharmaceutical preparations to accommodate various patient needs and therapeutic strategies. The most common dosage form(s) include oral tablets and sterile solutions for injection administered via intramuscular, subcutaneous, or intravenous routes. The general purpose of Metotrexato is to control severe disease activity by slowing down abnormal cellular proliferation and suppressing the chronic inflammation driven by an overactive immune system. For example, it is a mainstay treatment for patients requiring systemic control of severe rheumatoid arthritis or psoriasis.

Regulatory References

  1. National Institutes of Health, MedlinePlus

What side effects are possible with Metotrexato?

Possible Side Effects and Safety Information

The official safety profile for Metotrexato (Methotrexate) details potential adverse reactions across various body systems, which are categorized by frequency in regulatory documentation. Effects are tiered from Very Common to Rare, providing a formal understanding of expected risks.

Very Common adverse reactions (occurring in 10% or more of patients) include stomatitis (mouth sores), nausea, vomiting, and transient elevation of liver enzymes.

Common effects (occurring in 1% to less than 10% of patients) may involve headache, diarrhea, fatigue, and, notably, a serious risk of interstitial pneumonitis (lung inflammation). These adverse events are typically grouped by the System-Organ Class they affect, such as Gastrointestinal, Blood, and Hepatobiliary disorders.

Serious Adverse Reactions explicitly documented in official labels include severe myelosuppression (bone marrow suppression), hepatotoxicity (risk of fibrosis/cirrhosis with long-term use), and pulmonary toxicity. These serious risks necessitate close medical monitoring.

Population-Specific Safety: Official constraints dictate that the medicine is generally contraindicated in severe hepatic or renal impairment due to increased toxicity risk. It is also contraindicated in pregnancy for non-oncology uses due to documented embryo-fetal toxicity. Safety profiles note that certain effects, like gastrointestinal issues, may be more prominent at the initiation of treatment, while chronic issues, like liver damage, are associated with long-term exposure.

Overdose and Emergency Response

Methotrexate overdose can occur from taking more than the prescribed amount or, more commonly, due to a medication error where the weekly dose is accidentally taken daily. This can lead to severe and potentially fatal toxicity by affecting rapidly dividing cells in the body, such as those in the bone marrow and gastrointestinal tract.

Symptoms of Overdose/Toxicity

Symptoms of methotrexate toxicity may appear hours to days after the event. Immediate medical help is required if any of these signs appear:

System Symptoms
Gastrointestinal Severe nausea, vomiting, persistent diarrhea, mouth sores (stomatitis), gastrointestinal bleeding.
Hematologic Fever, chills, sore throat, easy bruising or unusual bleeding (signs of low blood cell counts).
Respiratory New or worsening dry cough, fever, shortness of breath.
Renal/Hepatic Significant decrease or increase in urination, yellowing of the skin or eyes (jaundice), severe fatigue.

When to Seek Help

Call your local emergency services immediately if you or someone else has taken a dose of methotrexate that is higher or more frequent than prescribed.

Also, seek urgent medical advice from your prescribing doctor or an emergency department if any severe toxicity symptoms, especially persistent gastrointestinal issues, signs of infection, or unusual bleeding, develop while on therapy. Treatment for severe toxicity, which may involve the administration of an antidote such as leucovorin (folinic acid) or glucarpidase, must be initiated as soon as possible.

Therapeutic Uses of Metotrexato

What Methotrexate Treats: Main Uses and Benefits

Methotrexate is a medication applied across several therapeutic domains for managing symptoms related to inflammatory or irritative states. Its use is primarily targeted at controlling symptoms that interfere with daily functioning and create noticeable physiological strain. The medication is relevant in clinical settings where supportive symptom management is appropriate and contributes to easing the overall symptom load. Its use is considered relevant in conditions characterized by periods of heightened symptoms.

The medicine is commonly used across conditions involving inflammatory or irritative processes. It is also applied in settings marked by temporary physiological imbalance. By addressing these issues, the medication assists with maintaining functional stability and provides supportive relief.

“It helps patients cope more steadily with symptom fluctuations by easing distress associated with persistent manifestations.”

Quick Fact: Focus on Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Metotrexato

Official regulatory documents define strict criteria for using Methotrexate, primarily through a non-negotiable list of contraindications and population-specific restrictions.


Eligibility Scope

Classification Official Regulatory Statement
Populations for whom use is allowed Adults with severe rheumatoid arthritis or psoriasis, and Pediatric Patients (age 3+) for specific oncological and rheumatologic (pJIA) indications.
Populations for whom use is not recommended Children under 3 years of age due to insufficient data on efficacy and safety.
Populations for whom use is contraindicated Pregnant women (for non-neoplastic diseases) and nursing mothers.
Age-related eligibility rules Use in older adults requires extreme caution and dose reduction consideration due to potential decline in organ function.
Condition-specific eligibility rules Contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min), alcoholic liver disease, or pre-existing blood dyscrasias (e.g., severe leukopenia, significant anemia).

Eligibility-Related Restrictions

  • Reproductive Status: Mandatory use of effective contraception for both female and male patients of reproductive potential during and for a specified period after treatment.
  • Organ Function: Patients with moderate renal impairment (creatinine clearance 30-59 mL/min) or fluid accumulation (e.g., ascites) require dose adjustment and careful monitoring.
  • Immunity: Contraindicated in patients with immunodeficiency syndromes or current severe active infections (e.g., tuberculosis).

Connection to the overall eligibility profile

Regulatory documents structure eligibility by imposing absolute contraindications based on reproductive status, critical organ function, and pre-existing blood or immune conditions. Use in approved populations is conditional, requiring adherence to strict age- and function-based adjustments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Methotrexate's interaction profile is primarily defined by its effects on systemic exposure and the risk of additive toxicity, as documented in regulatory guidelines.

Classification Clinically Significant Interacting Products
Increased Exposure Risk NSAIDs (e.g., Ibuprofen, Naproxen): Co-administration may elevate and prolong serum MTX levels, increasing toxicity risk. Proton Pump Inhibitors (PPIs) (e.g., Omeprazole): Concomitant use may also delay MTX elimination and raise its concentration. Oral Antibiotics (e.g., Penicillins, Tetracyclines): May reduce MTX renal elimination.
Additive Toxicity Risk Other Hepatotoxic Agents (e.g., Fluconazole): Increases the risk of liver damage. Radiotherapy: May increase the risk of soft tissue necrosis and osteonecrosis. Other Antifolates (e.g., Trimethoprim/Sulfamethoxazole): Leads to increased antifolate effects, potentially causing bone marrow suppression.
Formal Contraindications Live Vaccines: Prohibited due to the risk associated with immunosuppression. Chronic Alcohol Consumption: Officially restricted due to the significant increase in hepatotoxicity risk.

Interaction Context and Restrictions

The most commonly documented mechanism is competition for renal tubular excretion sites, which leads to increased Methotrexate exposure. Folic Acid or Folinic Acid is a documented agent used to modulate and reduce specific MTX toxicities. Population-specific cautions apply to patients with impaired renal function or pathological fluid accumulation (such as ascites), as these conditions reduce MTX elimination, significantly increasing the risk of accumulation and unexpected toxicity. Monitoring is also required for elderly patients due to potentially diminished clearance.

Mechanism of Action

Methotrexate (MTX) employs a dual-action strategy to modulate immune activity and cellular growth by interfering with fundamental metabolic and signaling pathways.

The primary molecular action is the competitive inhibition of the enzyme dihydrofolate reductase (DHFR). This blockade prevents the formation of essential tetrahydrofolate cofactors, which are necessary for the synthesis of DNA and RNA building blocks. This mechanism suppresses the multiplication of highly active cells, thus altering the signaling patterns that drive excessive cellular growth.

The anti-inflammatory effects are driven by active metabolites, Methotrexate Polyglutamates (MTX-PGs). These metabolites indirectly inhibit the enzyme ATIC (AICAR Transformylase), causing an increase in extracellular adenosine. Adenosine acts on specific adenosine receptors on immune cells, initiating a cascade that suppresses key inflammatory pathways and reduces the release of pro-inflammatory cytokines. This contributes to the systemic modulation of overactive immune signaling pathways.

However, the full functional activity is constrained by a slow, time-dependent process: the requirement for MTX-PGs to gradually accumulate inside the target cells to inhibit ATIC, which is an inherent limitation of this mechanistic cascade.

Dosage and Administration Information

Methotrexate administration is precisely governed by its therapeutic application, with major distinctions between low-dose and high-dose regimens. For inflammatory conditions like rheumatoid arthritis or psoriasis, the medicine is delivered on a strict once-weekly schedule as a single dose or divided into three doses over a 36-hour period. The dose is typically a fixed milligram amount, often starting at 7.5 mg and generally not exceeding 25 mg weekly, depending on the route and specific label.


The medicine is supplied as oral tablets and solutions for injection, facilitating administration via the oral, subcutaneous, or intramuscular routes. High-dose regimens used in oncology protocols introduce significant variability and require administration via intravenous infusion, frequently in a specialized hospital setting. The route of administration can also include intrathecal injection using a specific preservative-free formulation.


In specific use contexts, oral tablets may be taken with or without food. Furthermore, dose reduction is required for older adults or individuals with impaired renal function, and pediatric dosing is calculated based on Body Surface Area (BSA). For non-oncologic, low-dose use, folic acid supplementation is an integral part of the total regimen, instructed to be taken on days other than the Methotrexate dosing day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metotrexato


Evidence for use in Rheumatoid Arthritis

Researchers was studied for its use in adults with active Rheumatoid Arthritis using a wide array of study designs, including short-term and intermediate-term Randomized Controlled Trials (RCTs), as well as long-term observational studies. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort, systemic or functional imbalance, and daily functioning or activity level. Study populations included both patients new to treatment and those who had not responded well to previous conventional treatments.

In these trials, Metotrexato was observed in studies examining clinical disease activity measures and patient-reported outcomes describing perceived discomfort. RCTs reported measurements of change in inflammatory symptom scores over periods typically up to 12 months. Longer-term observational studies monitored how patients fared over multiple years, to track the measured outcomes.

However, long-term effects are not fully established, particularly concerning the final impact on joint integrity, as this information is often drawn from observational studies rather than highly controlled, extended RCTs. Also, comparative evidence is lacking in some areas when evaluating Metotrexato against newer targeted treatments over a long duration.


Evidence for use in Severe Psoriasis

The research evidence for Metotrexato in severe Psoriasis includes Randomized Controlled Trials (RCTs) and Systematic Reviews. Primary outcomes were evaluated in trials based on measures of skin clearance and disease severity, notably the Psoriasis Area and Severity Index (PASI scores). Short-term trials reported how symptoms evolved in the observed populations over time, with measurements of skin severity indices at time points ranging from 12 to 24 weeks.

Despite its long clinical history, the evidence base contains fewer large, long-term RCTs compared to studies for rheumatoid arthritis, and evidence quality varies across studies. Trial designs and reported dosing schedules have historically shown heterogeneity (variability), which can limit synthesis across studies.


Research in Special Populations

Specific research was studied for Metotrexato in distinct populations, notably pediatric patients with Juvenile Idiopathic Arthritis (JIA). Studies in this pediatric population are constrained by smaller sample sizes compared to adult trials. For older adults, long-term patient registries and observational studies were observed in to track outcomes, recognizing that subgroup findings are uncertain in relation to co-existing health conditions (comorbidities) in these cohorts.

Key Studies & References

  1. Psoriasis: assessment and management (NICE Guideline CG153)

Frequently Asked Questions (FAQ)

Common questions about Metotrexato (FAQ)

Q: What happens if I miss a weekly dose of Metotrexato?

Official patient safety instructions provide guidance if a dose is missed. For the once-weekly regimen, official guidance is to take the dose if it is remembered on the next day or the day after the scheduled date. If the dose is remembered more than two days late, official guidance advises skipping the missed dose and taking the next one on the usual scheduled day. Regulatory instructions state that two doses must never be taken together.

Q: How long after stopping Metotrexato is it safe to try for pregnancy?

Due to the risk of documented embryo-fetal toxicity, the requirement is for both men and women to use effective contraception during and after treatment. Official guidelines generally recommend waiting at least three months after the final dose before attempting to conceive. Some manufacturers recommend waiting up to six months for women.

Q: Can Metotrexato cause hair loss?

Yes, hair loss (alopecia) is a documented side effect, according to official adverse reaction listings. It is generally uncommon, typically affecting a small percentage of patients (1% to 3%). This effect is usually described as mild and may resolve after the medication is discontinued.

Q: Will Metotrexato make me more sensitive to the sun?

Official safety warnings indicate that Metotrexato can increase skin sensitivity to sunlight (photosensitivity). Regulatory warnings include the general recommendation to use sun protection, wear protective clothing, and avoid sun lamps or tanning beds while on this medication.

Q: How soon after starting Metotrexato should my doctor check my liver function?

Regulatory and clinical monitoring guidelines require intensive testing, especially during the initial phase of treatment. Initial monitoring often involves blood tests (including full blood counts and liver/kidney function tests) and is typically repeated every 2 to 6 weeks, shifting to monthly or every three months based on the physician's prescribed schedule.

Q: Does taking Metotrexato require special precautions when around sick people?

Because Metotrexato affects the immune system, it is classified as an immunosuppressant, which can potentially increase the risk of infection. General patient safety advice for immunosuppressed individuals includes taking precautions, such as minimizing contact with people who are sick or have active infections.

Q: Is Metotrexato a steroid?

No, Metotrexato is not a steroid. It is classified as an antifolate and an antimetabolite drug, meaning its mechanism of action interferes with cell metabolism and is distinct from corticosteroids.

Q: Is Metotrexato the same as the drug used for ectopic pregnancy?

Yes, official regulatory documents confirm that Metotrexato (Methotrexate) is an approved treatment option for ectopic pregnancy. It is used in this setting to manage the cellular growth associated with the condition.

Q: Are there any common supplements that interact with Metotrexato?

Official drug interaction guides indicate that certain compounds in supplements, such as White Willow, St. John's Wort, and certain Citrate compounds, may interact with Metotrexato. General regulatory guidance advises caution and consultation before combining Metotrexato with any herbal remedies or supplements.

Q: Is Metotrexato a form of chemotherapy?

Metotrexato is classified as an antineoplastic agent (a class often used in chemotherapy) when administered at high doses to treat cancer. When used at lower doses for autoimmune diseases, it is classified as an immunosuppressant and a Disease-Modifying Antirheumatic Drug (DMARD).

Q: Does Metotrexato treat the cause of the disease or just the symptoms?

According to the drug's mechanism of action, it works by suppressing the body's overactive immune system (addressing the underlying mechanism of the disease) and, as a result, reducing the associated inflammation and pain (treating the symptoms).

Q: What is the maximum duration a patient can stay on Metotrexato?

There is no officially specified maximum duration of use in regulatory documents. However, continuous long-term treatment requires continuous and regular medical monitoring due to the risk of cumulative liver toxicity.

Q: How long does it typically take to start feeling the effects of Metotrexato?

Official efficacy data indicate that the drug's full effect is constrained by a slow, time-dependent process. Studies for autoimmune conditions often measure improvement in disease activity over a period of 3 to 6 months.

Q: What types of birth control are recommended while on Metotrexato?

Official regulatory documents state the requirement for effective contraception for both partners during and after treatment due to serious risks. However, the product label does not typically specify the exact recommended types of birth control (e.g., hormonal or barrier methods).

Q: Does Metotrexato cause weight gain or loss?

Significant changes in body weight (gain or loss) are not commonly listed as a Very Common, Common, or Serious Adverse Reaction in the drug’s official side effect profile.

Q: Does Metotrexato interact with thyroid medication?

Regulatory and drug interaction databases do not list a major clinical interaction or contraindication between Metotrexato and the most common thyroid medications, such as levothyroxine.

How should Metotrexato be stored and disposed of?

Methotrexate storage and disposal instructions are regulated to maintain product stability and ensure safe handling of this cytotoxic agent.

Storage & Environmental Rules Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep in the original container, tightly closed, away from light and moisture.
Post-Puncture Stability Multi-dose injection vials must be refrigerated (2 C to 8 C) and used within 30 days after the first puncture.

Methotrexate must be stored out of the sight and reach of children.

Disposal Requirements: Because this is classified as a hazardous drug, unused or expired product must not be disposed of in household trash or wastewater. All used needles and syringes must be immediately placed into a dedicated, puncture-resistant sharps container. Consult a healthcare professional on how to properly discard any unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metotrexato found in:

A-Z Index: